Drug-like Index:  A New Approach To Measure Drug-like Compounds and Their Diversity

Jun Xu* and James Stevenson
Research & Development Center, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877-0368
J. Chem. Inf. Comput. Sci., 2000, 40 (5), pp 1177–1187
DOI: 10.1021/ci000026+
Publication Date (Web): August 2, 2000
Copyright © 2000 American Chemical Society
*

In papers with more than one author, the asterisk indicates the name of the author to whom inquiries about the paper should be addressed.

Abstract

Combinatorial organic synthesis (combinatorial chemistry or CC) and ultrahigh-throughput screening (UHTS) are speeding up drug discovery by increasing capacity for making and screening large numbers of compounds. However, a key problem is to select the smaller set of “representative” compounds from a virtual library to make or screen. Our approach is to select drug-like as well as structurally diverse compounds. The compounds, which are not very drug-like, are less taken into account or excluded even if they contribute to the diversity of the collection. Hence, the first step in the compound selection is to rank compounds in drug-like “degree”. To quantify the drug-like “degree”, drug-like index (DLI) is introduced in this paper. A compound's DLI is calculated based upon the knowledge derived from known drugs selected from Comprehensive Medicinal Chemistry (CMC) database. The paper describes the way of this knowledge base is formed and the procedure for selecting drug-like compounds.

Tools

SciFinder Links

SciFinder subscribers:  Click to sign in | Not a SciFinder subscriber? Learn more at www.cas.org

History

  • Published In Issue September 25, 2000
  • Received March 23, 2000

Recommend & Share

Related Content

Other ACS content by these authors: